Trifarotene cream effective for face, trunk acne
Trifarotene is safe, well-tolerated and effective in treating both facial and truncal acne, according to two phase III trials.
Researchers conducted two double-blinded, randomized, vehicle-controlled trials: PERFECT 1 (n=1,208; mean age, 19.4±6.41 years; 52.1 percent female) and PERFECT 2 (n=1,212; mean age, 19.7±6.3 years; 57.3 percent female). In both studies, the primary endpoints were success rate on the face, as measured by the Investigator’s Global Assessment (IGA), and the absolute change from baseline in inflammatory and noninflammatory counts.
In PERFECT 1, the IGA success rate in the face in patients who received the trifarotene cream (n=612) was 29.4 percent. This was significantly higher than the corresponding rate in those randomly assigned to the vehicle cream (19.5 percent; p<0.001). A similar trend was observed for PERFECT 2 (42.2 percent vs 25.7 percent; p<0.001).
Trifarotene continued to trump the vehicle control in terms of primary endpoints. For instance, in PERFECT 1, there was a significantly greater absolute drop in inflammatory lesions in those who received the cream of interest (–19.0 vs –15.4; p<0.001). This remained true in PERFECT 2 (–24.2 vs –18.7; p<0.001).
Noninflammatory lesions likewise significantly decreased from baseline in both PERFECT 1 (–25.0 vs –17.9; p<0.001) and PERFECT 2 (–30.1 vs –21.6; p<0.001).
The significant benefits of trifarotene also extended to the trunk. The Physician’s Global Assessment success rates (PERFECT 1: 35.7 percent vs 25.0 percent; p<0.001; PERFECT 2: 42.6 percent vs 29.9 percent; p<0.001) and reductions in inflammatory (PERFECT 1: –21.4 vs –18.8; p<0.001; PERFECT 2: –25.5 vs –19.8) and noninflammatory (PERFECT 1: –21.9 vs –17.9; p<0.001; PERFECT 2: –25.9 vs –20.8; p<0.001) lesions were all significantly greater in those who received the trifarotene cream.